Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedImmune LLC
With
RTI International
* To evaluate the rate of FluMist administration compared to other influenza vaccine use in the following pediatric populations:
* Children younger than 24 months of age
* Children 24-59 months of age with a claim associated with a diagnosis of asthma
* Children 24-59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing
* Children 24-59 months of age with immunosuppression
* To describe, in children in the above populations who receive FluMist, the type and number of Emergency Room visits or hospitalizations associated with an insurance claim within 42 days of receiving FluMist
* To explore the rationale for FluMist immunization of pediatric populations that are excluded from recommended usage by characterizing the use in these populations
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Children less than 24 months of age during August through January/February.
Children \<24 to 59 months of age during August through January/February, with:
* two outpatient claims for asthma, or
* one inpatient/emergency room claim for asthma, or
* one outpatient claim for asthma and at least one SABA prescription during a defined 12-month period.
Children \<24 to 59 months of age during August through January/February, without any claims associated with a diagnosis of asthma, but with at least one dispensing for SABA, as indicated by pharmacy claims during a defined 12-month period.
Children 24 to 59 months of age during August to January/February with evidence of immunosuppression prior to the date of influenza vaccination based on available medical and pharmacy claims.